Theravance Biopharma

About:

Theravance Biopharma is a biopharmaceutical company with one approved product.

Website: https://www.theravance.com/

Top Investors: Lauder Partners, Woodford Investment Management

Description:

Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. In addition, they have an economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of umeclidinium (UMEC), vilanterol (VI) and fluticasone furoate (FF) (UMEC/VI/FF), the combination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) GSK961081 (‘081) and FF (‘081/FF), and MABA monotherapy.